Full Printable Schedule-at-a-Glance (Updated: 6/09/14)Register

Tuesday, July 8—Solid Organ Transplant
Wednesday, July 9—Oncology and BMT

TUESDAY, JULY 8, 2014—SOLID ORGAN TRANSPLANT—GRAND BALLROOM SOUTH (Up to 6.0 credits are available.)

7:00 a.m.

Registration and Continental Breakfast—Exhibits Open, Grand Ballroom Prefunction

8:00 a.m.

Welcome and Opening Remarks, Cory Shaw, Senior Vice President of System Provider Network, The Nebraska Medical Center

8:30 a.m.

Where Is Health Care Reform in 2014? Alan Langnas, DO, University of Nebraska Medical Center
The Affordable Care Act outlining health care reform is one of the hottest topics across the country. What are hospitals and transplant centers doing to measure and improve their quality of care? As current president of the American Society of Transplant Surgeons, Dr. Langnas will discuss the possible changes that may affect transplantation and how centers must prepare in order to optimize performance in the face of reform.

Objectives:

  • Outline the potential changes in the Affordable Care Act.
  • Describe proactive processes that transplant programs can implement to improve quality and meet the Centers for Medicare/Medicaid Services (CMS) requirements.
  • Identify the challenges providers and patients will face in light of health care reform and quality-improvement initiatives.

9:15 a.m.

Understanding Living Kidney Donation, Ketki Tendulkar, MD, University of Nebraska Medical Center, and Regina Rau, RN, BSN, The Nebraska Medical Center
Studies show patients receiving a kidney from a living donor have an overall higher transplant success rate than those who receive a kidney from a deceased donor. Dr. Tendulkar and Nurse Coordinator Regina Rau will discuss the benefits and risks involved in living donor kidney transplantation.

Objectives:

  • Identify the donor evaluation process and who can donate.
  • Review examples of the different types of living donor transplants.
  • Summarize the benefits of living kidney donation.

10:00 a.m.

Break—Exhibits Open, Grand Ballroom Prefunction

10:30 a.m.

Lung Transplantation and the Challenge of Chronic Rejection (CR), Michael Moulton, MD, University of Nebraska Medical Center
Lung transplantation is established and effective palliative therapy for patients with certain end-stage lung diseases; yet, the long-term efficacy of lung transplantation is limited by the development of CR. This presentation will examine the indications for and outcomes after lung transplant. New insights into CR after lung transplantation will also be discussed.

Objectives:

  • Recognize indications for lung transplantation.
  • Examine outcomes after lung transplantation.
  • Define CR after lung transplant and new (and old) therapies for CR.
11:15 a.m.

Diagnosing and Treating Pancreatitis, Luciano Vargas, MD, University of Nebraska Medical Center
Patients with severe debilitation pancreatitis can now find relief and support through a multidisciplinary approach to pancreatitis. Dr. Vargas will discuss the complexity of diagnosis and treatment of chronic pancreatitis and indications for autologous islet cell transplant.

Objectives:

  • Explain pancreatitis and its causes.
  • Outline the treatment options for patients with chronic pancreatitis.
  • Indicate the benefits of auto-islet cell transplantation.

12:00 p.m.

Lunch (provided) Grand Ballroom North; Exhibits Open, Grand Ballroom Prefunction

1:15 p.m.

Intestinal Rehabilitation and Intestinal Transplantation: Working Together to Change the Lives of Children with Intestinal Failure, David Mercer, MD, PhD, FRCS(C), University of Nebraska Medical Center
Dr. Mercer will describe medical and surgical therapies that have redefined the outcomes for children with intestinal failure.

Objectives:

  • Summarize the common causes of intestinal failure.
  • State the medical and surgical options for managing short bowel syndrome.
  • Interpret the common perceptions about rehabilitation for children with extreme short bowel syndrome.
  • Recognize when intestinal transplantation is indicated.
2:00 p.m.

Cancer of the Liver and Bile Ducts, Wendy Grant, MD, University of Nebraska Medical Center
Transplant surgeons have a long history of taking care of patients with cancers of the liver and bile ducts. Innovative and aggressive approaches to treatment provide many options for care of patients with these cancers. Dr. Grant will discuss the surgical management of these patients and when transplantation can be considered.

Objectives:

  • Review cancers that occur in the liver and bile ducts.
  • Explain surgical management of liver and bile duct cancers.
  • Assess liver transplantation as a treatment option for patients with liver and bile duct cancer.

2:45 p.m.

Break—Exhibits Open, Grand Ballroom Prefunction

3:00 p.m.

Advancement in the Treatment of Patients with Hepatitis C, Timothy McCashland, MD, University of Nebraska Medical Center
The hepatitis C virus continues to be a concern for post-liver-transplant recipients. Dr. McCashland will share his expertise in the areas of diagnosis, prevention and treatment of hepatitis C in the posttransplant patient. In addition, his presentation will highlight new drug therapies and current research into the most effective treatment options.

Objectives:

  • Distinguish between the types of hepatitis C.
  • Recall the treatment and outcomes of recurrent hepatitis C in posttransplant patients.
  • Analyze the new therapeutic options in the treatment of hepatitis C patients.
3:45 p.m.

The Role of Genomic Medicine in Advanced Heart Failure, Brian Lowes, MD, PhD, University of Nebraska Medical Center
Genomic testing is becoming widely available and less expensive. Dr. Lowes will discuss the role of genetic testing in patients with advanced heart failure and review genetic testing and counseling.

Objectives:

  • State the clinical categories of inherited cardiomyopathies and describe their genetic basis.
  • Discuss the availability and appropriate utilization of genetic testing in heart failure patients.
  • Explain the role of the genetic counselor in the genetic testing process.

4:30 p.m.

Adjourn

WEDNESDAY, JULY 9, 2014—ONCOLOGY and BMT—GRAND BALLROOM SOUTH (Up to 6.5 credits are available.)

7:00 a.m.

Registration and Continental Breakfast—Exhibits Open, Grand Ballroom Prefunction

8:00 a.m.

Welcome and Opening Remarks, Theresa Franco, RN, MSN, Executive Director of Cancer Care Services, The Nebraska Medical Center

8:30 a.m.

The Evolving Landscape in Transplantation: Current Issues, Future Trends, Matthew A. Lunning, DO, University of Nebraska Medical Center
Blood and marrow stem cell transplantation is an important treatment option for an increasing number of malignant and nonmalignant disorders. Dr. Lunning will first review the process for deciding the type of transplant and/or preparative regimen. He will then review the evidence supporting transplantation as a treatment choice for various malignant diseases, including multiple myeloma, non-Hodgkin lymphoma and leukemia. Lastly, he will also speak about nonmalignant disorders wherein transplantation may be considered.

Objectives:

  • List three conditioning regimens commonly used in stem cell transplantation.
  • Distinguish disease and patient characteristics that may influence the type of blood stem cell transplant and preparative regimens utilized for transplant.
  • Recite three nonmalignant disorders that can be treated by blood stem cell transplantation.

9:30 a.m.

Personalized Medicine in Oncology, Warren Sanger, PhD, University of Nebraska Medical Center
The emergence of new tools for genome analysis has opened new opportunities for treating patients with cancer. The traditional nonspecific cytotoxic therapies are giving way to more targeted agents directed at unique molecular features of the cancer cell, generally termed “personalized medicine.” In this presentation, Dr. Sanger will discuss both what is current and what is anticipated for the future in the area of personalized medicine in oncology. He will also discuss some of the current and upcoming testing methods available to assist in diagnosis, prognosis, and treatment.

Objectives:

  • Explain current testing methods available to personalize cancer treatment.
  • Recall an example of tailored cancer treatment using a pharmaco-genomics approach.

10:15 a.m.

Break—Exhibits Open, Grand Ballroom Prefunction

10:45 a.m.

Lung Cancer Screening: Impacting Survival, Apar Kishor Ganti, MD, and Rudy P. Lackner, MD, University of Nebraska Medical Center
Lung cancer is the leading cause of cancer-related death in the United States and worldwide (National Comprehensive Cancer Network, 2014). Early detection of lung cancer is an important opportunity for decreasing mortality. While acknowledging that there are both risk and benefits, the NCCN recommends lung cancer screening for those individuals at high risk for developing the disease. They further recommend that institutions performing lung cancer screening use a multidisciplinary approach that includes an array of specialists.

Drs. Ganti and Lackner will discuss a comprehensive lung cancer screening program that includes properly identifying the high-risk individual, offering the appropriate screening, and if needed, treatment.

Objectives:

  • Outline the risk factors for lung cancer used to identify the high-risk populations that should be targeted for screening.
  • Compare the risks and benefits of lung cancer screening per the NCCN Lung Cancer Screening Guidelines (version 1.2014).
  • Summarize the impact of early diagnosis on overall survival and disease- and treatment-related morbidity.

12:00 p.m.

Lunch (provided)—Grand Ballroom North; Exhibits Open, Grand Ballroom Prefunction

1:15 p.m.

Grey Matters: The Principles of Brain Tumor Management, Michele R. Aizenberg, MD; Angela Gleason, PhD, APBB; Nicole Shonka, MD; and Weining (Ken) Zhen, MD, University of Nebraska Medical Center
In the year 2013, over 23,000 people in the United States were diagnosed with primary malignant brain and other central nervous system neoplasms. There are over 120 types of primary brain tumors with varied management strategies and anticipated outcomes. NCCN encourages a thorough multidisciplinary review of prognostic features and treatment options for each patient case.

A panel of experts will discuss the principles of managing brain tumors from initial imaging through selection of a treatment option. They will discuss the patient and disease characteristics considered when devising the treatment plan recommendation.

Objectives:

  • Recall two surgical options to be considered in the diagnosis and treatment of brain tumors.
  • Assess the treatment principles that guide the selection of surgical and/or radiation therapy for adults with brain tumors.
  • Recite two chemotherapy agents used in the treatment of select brain tumors and explain when they are indicated.
  • Identify indications for referral to neuropsychology in the treatment of the patient with a brain tumor.

2:15 p.m.

Hyperbaric Oxygen Therapy (HBOT) for Late Radiation Tissue Injury, Jeffrey Cooper, MD, University of Nebraska Medical Center
Radiation therapy is a treatment for many cancers, and some patients will experience late radiation tissue injury developing months or even years later. HBOT has been suggested as a treatment for these late effects as it improves the blood supply to these tissues and promotes healing. Dr. Cooper will give an overview of the indications for HBOT and give specific examples of the benefits for those patients with or at risk for tissue injury post radiation therapy.

Objectives:

  • List three indications for the use of HBOT.
  • Synthesize the benefits and harms of HBOT for treating or preventing late radiation tissue injury.
  • Demonstrate how HBOT is administered.

3:00 p.m.

Break—Exhibits Open, Grand Ballroom Prefunction

3:15 p.m.

Melanoma: The Basics and New Directions in Treatment, Alissa Marr, MD, University of Nebraska Medical Center
Dr. Marr will give an overview of melanoma, discussing incidence, mortality, risk factors and NCCN staging and treatment guidelines. She will discuss recent advances in immunotherapy and targeted agents used in the treatment of metastatic melanoma.

Objectives:

  • Paraphrase the epidemiology and risk factors for melanoma and how the disease is staged.
  • Discuss appropriate management of early-stage melanoma.
  • Describe new agents and/or targets in the treatment of metastatic melanoma.
4:15 p.m.

Targeted Molecular Radiotherapy: A New Therapeutic Approach, Janina Baranowska-Kortylewicz, PhD, University of Nebraska Medical Center
Radiolabeled monoclonal antibody therapy was one of the earliest steps in the delivery of cytotoxic radiation directly to cancer cells. The next step is the development of radiopharmaceutical conjugates capable of selective binding to intracellular molecular targets. Dr. Baranowska-Kortylewicz has been a pioneer in the research and development of these agents. In her presentation she will give an overview of the current status of the targeted molecular radiotherapy and the emerging role of this modality in the management of cancer. Some examples of the individualized treatment possibilities will also be shared.

Objectives:

  • Explore the history of the development of targeted radiotherapy.
  • Point out the current status of targeted molecular radiotherapy.
  • State two examples of individualized treatments with targeted molecular.

5:00 p.m.

Adjourn

Note: OptumHealth Education and The Nebraska Medical Center reserve the right to make any necessary changes to this program. Efforts will be made to keep presentations as scheduled. However, unforeseen circumstances may result in the substitution of faculty or content.
Last Updated: 6/09/14